What Kymos Pharma Services does

Kymos Pharma Services is a Barcelona-headquartered Contract Research Organization (CRO) founded in 2001, providing GLP-certified bioanalytical and GMP-certified CMC (Chemistry, Manufacturing and Controls) services to pharmaceutical, biotechnology, veterinary, cosmetic, and nutraceutical clients. The company operates four European laboratories — Kymos Spain (Cerdanyola del Vallès), Pharmaprogress in Italy, Prolytic in Germany, and the recently acquired Particle Analytical in Denmark — and added a representative office in Seoul, South Korea in December 2025. Under the 2024-established parent KYMOS GROUP, S.L., the group is structured to deliver analytical services across the full drug development lifecycle, from preclinical research through commercial manufacturing and regulatory submission.

The service portfolio is organized along two axes: development phase (Pre-Clinical & Clinical Services, Solid State Analysis, CMC Analysis & Quality Control) and molecule modality (Small Molecules, Biologics and Biosimilars, TIDES/Oligonucleotides & Peptides, and Cell & Gene Therapies). Capabilities include bioequivalence studies, pharmacokinetics, biomarker analysis, immunogenicity testing, biosimilar comparability, viral vector characterization, lipid nanoparticle testing, stability studies, and the newer solid-state/particle analysis line. The group is inspected by the FDA, EMA, and ANVISA, holds ISO 27001 and EU NIS 2 Directive compliance, and is led by founder/Chairman Joan Puig Corcoy and CEO Joan Puig de Dou.

The business model is project-based professional services, priced via custom quotations tied to scope, complexity, and turnaround, with multi-year contracts typical of regulated drug development engagements. Go-to-market is direct enterprise sales through scientific relationship management and presence at major industry events (CPHI, BIO-Europe, BioSpain, European Bioanalysis Forum). Named enterprise clients include Celltrion, PharmaMar, HELM, Combino Pharm, Exeltis, and Omeicos Therapeutics, with revenue derived entirely from contract research fees. No external funding rounds or disclosed financials are available, and the company is privately held.

Name

Kymos Pharma Services

Legal name

KYMOS GROUP, S.L.

Website

https://kymos.com

Company type

Private

Founded year

2001

Operating status

Operating

Headcount range

101–250 employees

Short description

Kymos Pharma Services is a Barcelona-headquartered analytical CRO providing GLP/GMP-certified bioanalysis and CMC services across small molecules, biologics, TIDES, and cell & gene therapies to pharmaceutical, biotech, and specialty chemistry clients globally.

Ownership category

akta.pro rank

Product category

Contract Research Organization (CRO) Services

NAICS

Testing Laboratories and Services (54138), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical Laboratories (621511)

SIC

Services-Testing Laboratories (8734), Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)

akta.pro primary industry

Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity) (HLAGAAAD)

akta.pro secondary industries

Bioanalytical Testing (PK/ADA/NAb) (HLAGADAA), Release Testing & Batch Certification (QC) (HLAGADAC), Central Laboratory & Clinical Trial Testing CROs (HLAGAAAE), Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA) (HLAGAKAA), Cell-Based & Potency Assays (Bioassays) (HLAGADAH)

Keywords

• Bioanalytical services
• CMC testing services
• Contract research organization
• Pharmaceutical quality control
• GMP analytical testing

Headquarters

HQ city

Barcelona

HQ country

Spain

HQ region

Europe

Offices6 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Contract Research Services: Project-based contract research services for bioanalysis and CMC testing throughout the product lifecycle, from early R&D to manufacturing and commercialization.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Kymos is an analytical Contract Research Organization (CRO) providing GLP-certified bioanalytical services and GMP-certified CMC and quality control testing for pharmaceutical, biotechnology, veterinary, fine chemistry, cosmetic, and nutraceutical sponsors. Offerings cover the full drug development lifecycle, from preclinical and clinical bioanalysis through commercial release testing, across multiple molecule classes including small molecules, biologics and biosimilars, TIDES (oligonucleotides and peptides), and cell & gene therapies, with additional solid-state analysis and characterization expertise.

Product overview

Kymos Group is an analytical Contract Research Organization (CRO) providing bioanalytical and CMC (Chemistry, Manufacturing and Controls) services across four European laboratories (Spain, Italy, Germany, and Denmark) and a South Korea office. The company operates as a unified service portfolio organized by molecule type (Small Molecules, Biologics and Biosimilars, TIDES/Oligo & Peptides, Cell & Gene Therapies) and service phase (Pre-Clinical & Clinical Services, Solid State Analysis, CMC Analysis & Quality Control). Services cover the entire drug product lifecycle from early research and development through manufacturing and commercialization, serving the pharmaceutical, biotechnology, veterinary, fine chemistry, cosmetic, and nutraceutical industries. The group is GLP- and GMP-certified and has been inspected by EMA, ANVISA, and FDA.

Differentiator

Problem solved

Functional benefit

Brands

• Prolytic: Kymos Germany subsidiary specializing in bioanalytical and CMC services
• Pharmaprogress
• Particle Analytical

Products and services

• Pre-Clinical & Clinical Bioanalysis Services GLP-compliant bioanalytical method development, validation, and sample analysis to support preclinical and clinical studies for pharmaceutical and biotechnology sponsors developing small molecules, biologics/biosimilars, TIDES, and cell & gene therapies.
• Solid State Analysis Characterization of the solid-state properties of drug substances and drug products for pharmaceutical clients, addressing questions of polymorphism, crystal form, and physical stability that are relevant to formulation and regulatory submissions.
• CMC Analysis & Quality Control GMP-certified CMC testing, release testing, stability studies, and quality control support for pharmaceutical, biotechnology, veterinary, cosmetic, nutraceutical, and fine chemistry clients across the product lifecycle.
• Small Molecules Services Bioanalytical and CMC services tailored to small molecule drug development, including method development, validation, and routine testing for pharmaceutical sponsors.
• Biologics and Biosimilars Services Bioanalytical and characterization testing for biologics and biosimilars, addressing the analytical needs of large molecule drug development including comparability and biosimilarity assessments.
• TIDES (Oligonucleotides and Peptides) Services Bioanalytical and CMC services for TIDES, covering oligonucleotides and peptides, including method development, validation, and testing for sponsors developing these therapeutic modalities.
• Cell & Gene Therapies Services Bioanalytical and characterization testing for cell and gene therapy programs, providing specialized analytical support for advanced therapy medicinal products (ATMPs) and viral vector characterization.

Named customers7 records

Segments5 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Particle AnalyticalcoreStrategic or Co-development Partner · 1 February 2026Kymos acquired Particle Analytical (Denmark) to strengthen particle analysis and solid state characterization services across Europe, expanding the group's capabilities in solid state analysis services.

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Eurofins Bioanalytical Services: Eurofins operates one of the largest global bioanalytical and CMC testing networks, including small-molecule and biologics LC-MS and immunoassay work. It competes head-to-head with Kymos on regulated bioanalysis, immunogenicity, and biosimilar comparability for pharma and biotech sponsors.
• Pharmaron: Pharmaron operates a fully integrated CRO/CDMO platform with bioanalytical labs in the US, UK, and China covering small molecules, biologics, and oligonucleotides. Its TIDES/bioanalytical offering and multi-country lab model put it in direct competition for the same enterprise accounts as Kymos.
• Celerion: Celerion is a specialist early-phase clinical and bioanalytical CRO with deep expertise in PK/PD, bioequivalence, and biomarker analysis. It directly overlaps Kymos's pre-clinical and clinical bioanalysis service lines for small molecules and biologics.
• Frontage Laboratories: Frontage offers bioanalytical, CMC, and biologics services across US and China labs, including integrated drug development support. Its integrated analytical-and-CMC model for small molecules and biologics is highly comparable to Kymos's full-lifecycle service catalog.
• SGS Health Sciences: SGS provides analytical, bioanalytical, and CMC testing services across a global laboratory footprint, including biologics characterization and clinical-trial-supporting assays. Its scope and multi-modality positioning closely mirror Kymos's bioanalysis-plus-CMC value proposition.

Broad incumbents

• Labcorp Drug Development: Labcorp's drug development business (formerly Covance) provides central labs, bioanalytical, and CMC services globally. It overlaps Kymos's central-lab and bioanalysis capabilities but typically as part of bundled clinical-trial service offerings to large pharma.
• IQVIA: IQVIA is the world's largest CRO with end-to-end clinical, bioanalytical, and real-world evidence services. While not a pure analytical specialist, it bids against Kymos for bioanalytical and central-lab work embedded in enterprise clinical packages.
• Intertek Pharmaceutical Services: Intertek provides GMP pharmaceutical and biopharmaceutical testing, including CMC, release testing, and particle analysis services globally. Its release-testing and particle-characterization capabilities directly overlap the CMC and Particle Analytical (Denmark) parts of Kymos's portfolio.
• WuXi AppTec / WuXi STA: WuXi AppTec is a global CRO/CDMO with bioanalytical and CMC services across small molecules, biologics, and advanced therapies. Although China-headquartered, its broad analytical platform competes with Kymos for European and US pharma outsourcing, particularly for biologics and ATMP work.
• Charles River Laboratories: Charles River is a global CRO offering bioanalytical, safety assessment, and manufacturing services across small molecules and biologics. It competes with Kymos on regulated analytical work but as part of a much broader discovery-through-manufacturing portfolio rather than as an analytical specialist.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/KymosPharma
• LinkedInlinkedin.com/company/kymos-pharma-services

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kymos Pharma Services